The Question
Imagine a couple with eleven embryos created through in vitro fertilisation. A company sequences each one and ranks them by predicted lifetime risk of type 1 diabetes, schizophrenia, heart disease, and other conditions. This is already a commercial service in the United States. Genomic Prediction, based in New Jersey, has offered polygenic embryo reports since 2019, and newer firms such as Orchid, Nucleus Genomics, and Herasight have followed, with prices reported to range from a few thousand dollars to as much as $50,000.
Pre-implantation genetic testing (PGT) has existed for decades, screening for chromosomal abnormalities and single-gene disorders like cystic fibrosis or Huntington's disease. What is new is the extension of this screening to complex polygenic traits — conditions shaped not by a single faulty gene but by hundreds or thousands of variants scattered across the genome. It is happening with very little public debate.
What the Evidence Shows
Pre-implantation genetic testing for monogenic disorders (PGT-M) has been offered since the early 1990s, screening for single-gene conditions such as Tay-Sachs, BRCA1/2 mutations, or Huntington's disease. Where parents carry a known mutation, this is widely accepted as therapeutic: it can spare a child serious inherited disease.
What changed is the arrival of polygenic risk scores (PRS) applied to embryos. These scores add up the small effects of many variants identified in large studies of adults. The best evidence suggests the gains are limited. A 2019 study in Cell by Shai Carmi's group at the Hebrew University of Jerusalem estimated that choosing the top-scoring of several embryos would gain, on average, only about 2.5 centimetres of height or 2.5 IQ points — with wide uncertainty. Scores are also less accurate for people of non-European ancestry, because most genetic studies have involved Europeans.
"We determined that at this time there is insufficient evidence of clinical utility of PGT-P."
— American College of Medical Genetics and Genomics, Points to Consider statement on polygenic embryo screening, 2024The He Jiankui case of 2018 showed how quickly the field can move into territory that alarms even its own practitioners. The Chinese biophysicist used CRISPR-Cas9 to edit embryos to disable the CCR5 gene, aiming to give HIV resistance; twin girls, Lulu and Nana, were born, and a third child followed. In December 2019, a Chinese court sentenced He to three years in prison. The scientific community's condemnation was near-unanimous: the science was premature, consent inadequate, and the risk of unintended edits unknown.
Selling parents a ranking of their embryos is easy. Proving that the ranking makes a meaningful difference to their child's life is much harder.
Why This Is Happening
The genomic data explosion. The UK Biobank, the US All of Us programme, deCODE Genetics in Iceland, and other biobanks have assembled genetic data on millions of people, linked to health records. This has made polygenic risk scores steadily more predictive for some conditions, though they still explain only part of the risk.
IVF is becoming more common. Assisted reproductive technology accounts for about 2.5% of US births, according to the Centers for Disease Control and Prevention, and roughly 400,000 cycles are performed each year in the United States. In a 2024 survey, many American IVF patients said they would use polygenic tests if they were free.
The regulatory vacuum in the United States. In Britain, the Human Fertilisation and Embryology Authority permits embryo testing only for listed serious conditions, and polygenic screening is not allowed; many European countries are similarly restrictive. The US has no equivalent national body, so polygenic embryo screening is legal and sold directly. Professional bodies have pushed back: the European Society of Human Genetics called it "an unproven, unethical practice" in 2021, and in 2024 the American College of Medical Genetics and Genomics said there was insufficient evidence of its clinical utility and did not recommend offering it.
What Could Happen
As costs fall and marketing grows, embryo polygenic scoring becomes a routine offering at IVF clinics in the United States and other permissive jurisdictions, despite professional opposition. No federal legislation passes. A two-tier reproductive medicine emerges between those who used IVF with selection and those who did not.
A clinic in a country outside the International Commission on the Clinical Use of Human Germline Genome Editing's reach — potentially in a Gulf state or Southeast Asia — offers CRISPR-based germline editing for a single high-penetrance disease variant. The first edited birth triggers an international crisis and accelerates calls for a global treaty. The technology's genie is already partially out of the bottle.
Marketing of embryo selection for predicted intelligence — already visible in 2025 subway advertising by Nucleus Genomics — triggers hearings, lawsuits, and state or federal rules restricting polygenic embryo selection to validated medical uses. The political coalition is unusual, spanning disability-rights groups, geneticists, and religious conservatives.
What Can We Do
The decisions being made in fertility clinics today will shape the biological composition of the next generation. How much selection is acceptable — and who gets to make that call — is one of the century's most consequential ethical challenges. But it is not unanswerable, and there are concrete steps societies can take now.
Establish a regulatory framework before the market is fully set. The US needs an equivalent of the UK's Human Fertilisation and Embryology Authority — a standing expert body with statutory power to approve or restrict new PGT applications. The longer Congress waits, the harder it becomes to unwind practices that are already widespread.
Mandate genetic counselling for all PGT-PRS procedures. Polygenic risk scores are probabilistic, not deterministic. A score that says an embryo has a 35% higher lifetime risk of schizophrenia does not mean that embryo will develop schizophrenia. Couples making irreversible decisions based on these numbers deserve independent, evidence-based counselling about what the numbers actually mean — not just a sales pitch from the company providing the test.
Fund disability rights and bioethics research in parallel with the science. The fastest-moving argument against expansive embryo selection comes not from religious conservatives but from the disability rights community, which argues that selecting against embryos with predicted disability traits sends a message that existing people with those conditions are less valuable. This is a serious argument that deserves serious institutional attention, not dismissal.
Address the equity problem now. If the children most likely to avoid genetic disease are those of educated, affluent IVF patients, we are building a genetic underclass by omission. Subsidised access to PGT for serious monogenic conditions — which several European countries already provide — is one mechanism. Broader deliberation about whether optimised reproduction should be a private luxury or a public health tool is overdue.
- Karavani E et al. — Screening human embryos for polygenic traits has limited utility, Cell, 2019
- News-Medical — ACMG statement on polygenic risk scores for embryo selection, February 2024
- ESHRE — Position statement on polygenic risk scores in embryo selection
- The Economist (via BizNews) — How much would you pay for a smarter baby?
- MIT Technology Review — Selling the sizzle of trait discrimination, December 2025